Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Interferon Gamma-1b for Pulmonary MAC Infection
NCT00021567Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2001
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary Mycobacterium avium complex infection comparing Interferon Gamma-1b with Placebo (2 arms). Primary endpoints: Safety and Tolerability at 48 weeks and Sputum Culture Conversion at 48 weeks. Started Jul 2001; status: completed.
02
Drugs
interferon gamma-1b
03
Conditions
pulmonary Mycobacterium avium complex infection
Beyond the preview
Go deeper on NCT00021567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00021567.